Showing all 15 results

  • Sale!



    Crysvita (burosumab) is indicated for the treatment of X-linked hypophosphatemia (XLH) and Tumor-induced osteomalacia (TIO).

  • Sale! Evkeeza



    Evkeeza (evinacumab) is an injectable medicine used together with other low-density lipoprotein (LDL)-lowering medicines in people aged 12 years and older with a type of high cholesterol called Homozygous Familial Hypercholesterolemia (HoFH).

    Evkeeza represents a significant advance in the treatment of high cholesterol. Its ability to target ANGPTL3 offers the potential for significant improvements in LDL-C levels, which could have a major impact on cardiovascular health.

  • Sale! Imcivree



    Imcivree (setmelanotide) is an advanced drug that offers hope to individuals with rare genetic disorders that cause obesity.

    It works by regulating the brain’s appetite regulation mechanism and has been shown to induce significant weight loss in clinical trials.

  • Sale! Isturisa



    Isturisa has shown immense potential in treating the symptoms associated with Cushing’s syndrome. It works by blocking the production of cortisol in the adrenal gland, leading to a reduction in cortisol levels in the bloodstream.

    Isturisa (osilodrostat) is a medication used for the treatment of adult patients with Cushing’s syndrome or for adults with Cushing’s disease who are not candidates for surgery, or who did not respond to prior surgery.

  • Sale! Kerendia



    Kerendia (finerenone) is a prescription medicine used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, nonfatal heart attacks and hospitalization for heart failure in patients with chronic kidney disease associated with type 2 diabetes..

    Kerendia represents a promising new treatment option for patients with CKD and T2D who are at risk of kidney and cardiovascular complications.


  • Sale! Leqvio



    Leqvio (inclisiran) is a medication used to reduce cholesterol levels in adults with primary hypercholesterolaemia or mixed dyslipidaemia.

    Inclisiran was approved for use in the European Union in December 2020.[6] In August 2021, it received NICE approval for use by the National Health Service in the UK. In December 2021, it was approved for medical use in the United States.

  • Sale! Nexviazyme



    Nexviazyme is an advanced form of alglucosidase alfa that shows promise as a more effective and tolerable treatment option for Pompe disease.

    Its enhanced stability, higher affinity for mannose-6-phosphate receptors, and improved pharmacokinetic properties enable it to penetrate muscle cells more efficiently and achieve better clinical outcomes.

  • Sale! Oxlumo



    Oxlumo (lumasiran) is a medication used to lower urinary oxalate levels in children and adults with primary hyperoxaluria type 1 (PH1).

    It is the first-ever therapy available for the treatment of patients with PH1.

  • Sale!

    Palynziq (pegvaliase-pqpz)


    Palynziq (pegvaliase-pqpz) is indicated for the treatment of phenylketonuria (PKU), to reduce blood phenylalanine concentrations in adult and adolescent patients from 16 years of age who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.

  • Sale! Roszet



    Roszet is a valuable medication option for managing high cholesterol levels and reducing the risk of cardiovascular diseases associated with high cholesterol levels.

    Talk to your healthcare provider to determine if Roszet is an appropriate medication option for you.

  • Sale!

    Vascepa (icosapent ethyl)


    Vascepa (icosapent ethyl) is a prescription medicine used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of of cardiovascular events.

  • Sale! Voxzogo



    Voxzogo is expected to become a vital medication in the treatment of this condition.

    Its advanced effects and targeted mechanism of action make it a highly effective and innovative medication that promises to improve the lives of individuals with achondroplasia and offer new hope to those who have long been struggling with this condition.

  • Sale! Waylivra



    Waylivra (volanesorsen) is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and plasma triglycerides lowering therapy has been inadequate.

    Volanesorsen is indicated as an adjunct to diet in adults with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.



  • Sale! Zegalogue



    Zegalogue represents a significant advance in the field of diabetes care, providing an innovative new treatment for severe hypoglycemia that is both more effective and easier to use than traditional glucagon products.

    However, Zegalogue had fewer instances of vomiting and nausea, a common side effect seen in traditional glucagon treatment.

  • Sale! Zokinvy



    Zokinvy (lonafarnib) is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome (HGPS) or certain types of Progeroid Laminopathies in patients one year of age and older.

    It is the first FDA-approved medication for these diseases.